Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H9NO2 |
Molecular Weight | 151.1629 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=Nc1ccc(cc1)O)O
InChI
InChIKey=RZVAJINKPMORJF-UHFFFAOYSA-N
InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. Acetaminophen (USAN) or Paracetamol (INN) is a widely used analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. At therapeutic doses, acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, kidney function, or the fetal ductus arteriosus (as NSAIDs can). Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. Acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells, which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works. The antipyretic properties of acetaminophen are likely due to direct effects on the heat-regulating centers of the hypothalamus resulting in peripheral vasodilation, sweating and hence heat dissipation.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=15662292 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5798721E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43 μg × h/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.4 h |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/ Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 2300 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 5300 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
major | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1500 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1900 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 2300 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 3700 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 4000 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 5500 uM] | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. | 1979 Feb 10 |
|
Paracetamol-induced fulminant hepatic failure in a child after 5 days of therapeutic doses. | 1999 |
|
Assay to detect inhibitory substances in serum of patients with acute liver failure. | 1999 Feb |
|
Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. | 1999 Jul |
|
Acetaminophen (paracetamol) levels in human tears. | 1999 Oct |
|
The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. | 2000 Apr |
|
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. | 2000 Aug |
|
Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. | 2000 May |
|
N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). | 2000 May-Jun |
|
Establishment of a human hepatoma cell line, HLE/2E1, suitable for detection of p450 2E1-related cytotoxicity. | 2000 Oct |
|
Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. | 2000 Oct |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
p-Aminophenol-induced liver toxicity: tentative evidence of a role for acetaminophen. | 2001 |
|
Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. | 2001 Feb |
|
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro. | 2001 Feb |
|
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics. | 2001 Feb |
|
Thermodynamic analysis of compact formation; compaction, unloading, and ejection. II. Mechanical energy (work) and thermal energy (heat) determinations of compact unloading and ejection. | 2001 Feb 1 |
|
Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat. | 2001 Feb 1 |
|
Acetaminophen toxicity induced non-oliguric acute tubular necrosis. | 2001 Jan |
|
Simultaneous determination of paracetamol and methocarbamol in tablets by ratio spectra derivative spectrophotometry and LC. | 2001 Jan |
|
NSAID impairment of orthodontic tooth movement. | 2001 Jan |
|
Separation of cold medicine ingredients by capillary electrophoresis. | 2001 Jan |
|
Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. | 2001 Jan |
|
Successful use of propranolol in migraine associated with electroconvulsive therapy. | 2001 Jan |
|
The dark side of a 'detoxification' mechanism. | 2001 Jan |
|
Gastric emptying in diabetic gastroparetic dogs: ffects of SK-951,a novel prokinetic agent. | 2001 Jan |
|
Safety of childhood acetaminophen overdose. | 2001 Jan |
|
High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. | 2001 Jan |
|
Causes of Alzheimer's disease: paracetamol (acetaminophen) today? Amphetamines tomorrow? | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Prevention of acetaminophen-induced liver toxicity by 2(R,S)-n-propylthiazolidine-4(R)-carboxylic acid in mice. | 2001 Jan 15 |
|
Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. | 2001 Jan 26 |
|
Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis? | 2001 Jan 8 |
Patents
Sample Use Guides
2 caplets every 8 hours with water; don't take more than 6 caplets in 24 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10751557
A time- and concentration-dependent decrease in intracellular GSH occurred in freshly isolated type II pneumocytes and alveolar macrophages exposed to subtoxic (= 1 mM) APAP concentrations.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02AJ17
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
CFR |
21 CFR 341.40
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-VATC |
QN02BE71
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
NCI_THESAURUS |
C2356
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-VATC |
QN02BE01
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ06
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
CFR |
21 CFR 862.3030
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02BE71
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
EPA PESTICIDE CODE |
606318
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-VATC |
QN02BE51
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
LOINC |
75071-1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02BE51
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02BE01
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ13
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
LIVERTOX |
8
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
||
|
WHO-ATC |
N02AJ01
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09611MIG
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
103-90-2
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
1983
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
DB00316
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
PARACETAMOL
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
8055-08-1
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
SUPERSEDED | |||
|
Acetaminophen
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
M1317
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | Merck Index | ||
|
ACETAMINOPHEN
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Sparingly soluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R; practically insoluble in ether R. Category: Analgesic; antipyretic. Storage: Paracetamol should be kept in a tightly closed container, protected from light. Definition: Paracetamol contains not less than 98.5% and not more than 101.0% of C8H9NO2, calculated with reference to thedried substance. | ||
|
626
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
203-157-5
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
362O9ITL9D
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
1003009
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | USP-RS | ||
|
CHEMBL112
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
52
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
161
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | RxNorm | ||
|
3001
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
D000082
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
103-90-2
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
5239
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY | |||
|
C198
Created by
admin on Fri Jun 25 21:05:34 UTC 2021 , Edited by admin on Fri Jun 25 21:05:34 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE TOXIC (PARENT)
PARENT (METABOLITE ACTIVE)
PARENT (METABOLITE ACTIVE)
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)